GoodRx Holdings, Inc. (NASDAQ:GDRX), a company specializing in computer processing and data preparation, announced a change in its executive team earlier this week. Karsten Voermann has resigned as Chief Financial Officer for personal reasons, effective January 17, 2025. The company clarified that his resignation was not due to any disagreement with the company's operations, policies, or practices.
Following Voermann's departure, GoodRx's Board of Directors has named Romin Nabiey as the Interim Chief Financial Officer, starting from Voermann's exit date. Nabiey, who is currently serving as the Chief Accounting Officer, will retain his role alongside his new responsibilities as the principal financial officer.
Nabiey, 38, has been with GoodRx since April 2022 and has held various controllership roles within the company. His experience includes significant positions at Doctor Evidence, LLC, NantWorks, LLC, and auditor responsibilities at Ernst & Young. Nabiey holds a B.A. in Accounting and Finance from California State University, Fullerton, and is a licensed CPA.
The company disclosed that there are no familial ties or material transactions involving Nabiey that would require disclosure under SEC regulations. He has also entered into the company's standard indemnification agreement for directors and officers.
In connection with Voermann's departure, GoodRx is expected to finalize a Separation Agreement & Release. The agreement will allow Voermann to exercise his vested stock options until January 17, 2026, and he will be eligible to receive his earned 2024 annual cash incentive bonus. Voermann will release GoodRx from any claims related to his employment, except for those that cannot be waived by law, and will continue to be bound by an agreement containing confidentiality and intellectual property assignment covenants.
The information in this article is based on a recent SEC filing by GoodRx Holdings, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.